Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The relationship between clinical severity of Noonan's syndrome and growth, growth hormone (GH) secretion and response to GH treatment.

Journal of pediatric endocrinology & metabolism : JPEM - 1 Feb 2002

Noordam Kees, van der Burgt Ineke, Brunner Han G, Otten Barto J

Abstract excerpt

Short stature is one of the major features of Noonan's syndrome (NS). In a multicentre trial of growth hormone (GH) therapy in 25 children with NS, we observed a large inter-individual variation in first-year response to GH treatment. This suggested that subgroups might exist in NS that differ in either endogenous GH status or responsiveness to GH therapy. We therefore related growth, GH secretion and 2 years...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Growth

Share to Human Growth Hormone

Share to Noonan Syndrome

Share to Phenotype

Share to Treatment Outcome

Source

Identifiers

PMID: 11874182
DOI: 10.1515/jpem.2002.15.2.175

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The relationship between clinical severity of Noonan's syndrome and growth, growth hormone (GH) secretion and response to GH treatment.PMID 11874182Read ↗

Efficacy and safety of growth hormone therapy in children with Noonan syndrome.Semantic proximity Read ↗

Noonan syndrome: relationships between genotype, growth, and growth factors.Semantic proximity Read ↗

Noonan syndrome spectrum disorders in real life: patient characteristics and response to growth hormone therapy in a genetically defined single-country multicenter cohort.Semantic proximity Read ↗

Achieving Optimal Short- and Long-term Responses to Paediatric Growth Hormone TherapySemantic proximity Read ↗

Abnormal growth in noonan syndrome: the challenge of optimal therapy.Semantic proximity Read ↗

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.Semantic proximity Read ↗

GH Responsiveness in Children With Noonan Syndrome Compared to Turner Syndrome.Semantic proximity Read ↗

GH therapy in Noonan syndrome: Review of final height data.Semantic proximity Read ↗

PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.Semantic proximity Read ↗

Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.Semantic proximity Read ↗

Noonan syndrome, the Ras-MAPK signalling pathway and short stature.Semantic proximity Read ↗

Clinical Heterogeneity in two patients with Noonan-like Syndrome associated with the same SHOC2 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.